Introduction
Interleukin-10 (IL-10) is a cytokine most recognized for its anti-inflammatory properties.
IL-10 achieves this suppression of inflammatory responses by inhibiting the expression of MHC class II, co-stimulatory molecules and proinflammatory cytokines in APCs (1) .
This inhibition of APC function in turn limits the magnitude of T cell responses. In addition, IL-10 directly inhibits the activation and cytokine secretion of CD4+ T cells (2) (3) (4) . The absence of IL-10 can lead to increased tumour clearance in response to intratumoral CpG injection (5), stronger T cell immunity induced by tumor cell vaccines (6) and it has been suggested that IL-10 contributes to the immune-suppressive environment of tumors.
Contrasting these findings, local release of IL-10 from transfected tumor cells (7) (8) (9) (10) or therapeutic administration of IL-10 induces strong anti-tumor immune responses and leads to tumor rejection in a variety of mouse tumor models (11) (12) (13) .
Despite these findings, IL-10's direct target cell types and their location in vivo have not been identified. We and others have previously shown that the anti-tumor effect of IL-10 depends on CD8+ T cells (7, 9, 10, 12) . In vitro, IL-10 induces the proliferation and cytotoxic activity of CD8+ T cells and is a chemoattractant for CD8+ T cells (14) (15) (16) (17) . 
Materials and Methods

Mice
Female C57BL/6 and BALB/c mice were obtained from The Jackson Laboratory. C57BL/6 IL-10Rb-/-, C57BL/6 OT-I, OT-I Rag1-/-CD45.1+/-and OT-I Rag1-/-IL10Rb-/-CD45.1+/+ mice were maintained under specific pathogen-free conditions at the animal facility of MRL/PA.
For the generation of mixed bone marrow chimeras lethally irradiated CD45.2+/+ hosts received 5x10 6 bone marrow cells containing 50% from wildtype (WT) CD45.2+/+ donors and 50% from IL-10Rb-/-CD45.1+/+ donors.
All animal procedures were approved by the IACUC of MRL/PA in accordance with guidelines of AAALAC.
Tumor models
To generate the PDV6-OVA tumor cell line parental PDV6 cells (18) were transfected with a plasmid expressing a CMV promoter driven cytoplasmic form of OVA (cOVA; amino acids 20-145) (19) .
Tumor implantations were done as previously described (12) . Tumors were left untreated for at least 10 days before injection with 5-10μg of DNA using a hydrodynamic technique.
PEG-IL-10 was injected at 0.1mg/kg twice a day. CD8 T cell depletion was done as previously described (12) . FTY720 (Cayman Chemical) was dissolved in 20% 2-Hydroxypropyl-β-cyclodextrin (Sigma) in PBS. A dose of 1mg/kg was administered by i.p. injection three times per 6 week. Tumor growth was monitored twice per week, recorded as 0.5 x length × (width) 2 and plotted as mean tumour volume ± SEM.
Tumor-infiltrating immune cell analysis and flow cytometry.
Single-cell suspensions from tumors and lymph nodes were generated (12) and were directly used for flow cytometry analyses. To analyze STAT activation 5-7 tumors were pooled and T cells were purified by positive selection with anti-CD90 MACS multi-sort microbeads followed anti-CD45 MACS microbeads according to the manufacturer's instructions (Miltenyi). Purified TILs were rested in 10% FCS, IMDM overnight followed by a 20 min stimulation with 100ng/ml mouse IL-10 (R&D).
Fluorescence-labeled antibodies against CD11b, CD8a, CD4, CD45, CD45.2, IL-10Ra, NK1.1, IFNγ, STAT1(pY701), STAT3(pY705), STAT4(pY693) , STAT5(pY694) and BrdU were all purchased from BD Biosciences. Antibodies to CD45.1 and Foxp3 were purchased from e-Bioscience. For detection of intracellular IFNγ, cells were stained without further in vitro restimulation using the Cytofix/Cytoperm kit (BD Biosciences).
Intracellular staining kits for BrdU (BD), Foxp3 and Phospho-STAT (Phosflow, BD) were used according to the manufacturer's instructions. Flow cytometry data were acquired on a FACSCantoII (BD) and analyzed with FlowJo software (Tree Star).
IL-10 Minicircle
The p2øC31.RSV.hAAT.bpA plasmid (encoding humanα1 anti trypsin) was provided by Dr. Zhi-Ying Chen (Stanford University, CA). For IL-10 minicircle the hAAT was replaced with mIL10 cDNA. Plasmids using the Ubiquitin promoter instead of the RSV 7 promoter were also generated. Injection of both minicircles resulted in comparable IL-10 serum levels.
Minicircle DNA production followed (20) with minor modifications.
Adoptive T cell transfer
Splenocyte suspensions of WT (CD45.1+/-) and IL-10Rb-/-(CD45.1+/+) OT-I mice were adoptively transferred into congenic hosts (CD45.2+/+) bearing PDV6-OVA tumors via tail vein injection. The frequency of Tg CD8+ T cells was determined by FACS before transfer and equal numbers of WT and IL-10Rb-/-CD8+ OT-I T cells were transferred.
In vitro activation of CD8+ OT-I T cells
Splenocyte suspensions of C57BL/6 OT-I mice were activated with 1 μg/ml SIINFEKL peptide (Bio-Synthesis) in 24 well plates.
Gene expression analysis and statistical methods
All mRNA analysis was performed using quantitative RT-PCR as previously described (12) . Statistical analysis was performed using Prism software.
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Results
IL-10 treatment induces activation of CD8+ T cells and tumor rejection
We have recently shown that pegylated IL-10 (PEG-IL-10) controls tumor growth and induces tumor rejection in a wide variety of tumor models (Suppl. Fig.1A ) (12) . mRNA analysis of tumors from control and IL-10 treated mice revealed that IL-10 induces a strong increase in the expression of the cytotoxic effector molecules Granzyme B and Perforin and of the effector cytokine IFNγ. In contrast, IL-10 induced only minor changes of these effector molecules in the tumor draining lymph node (TdLN) (Suppl Fig.1B ).
Isolation of inflammatory cells from tumors showed that PEG-IL-10 induced an increased presence of intratumoral CD8+ T cells (Suppl Fig.1C ). Antibody mediated ablation of CD8+ T cells abrogated tumor rejection (Suppl Fig.1D ). However, most tumor models required PEG-IL-10 to be administered twice a day, making the usage of PEG-IL-10 for further mechanistic studies tedious and financially prohibitive. Therefore we used the hydrodynamic delivery of an IL-10 encoding minicircle plasmid (21) to further study the molecular mechanisms underlying the potent anti-tumor efficacy of IL-10. The location of the delivery and expression of such intravenously injected plasmids is predominantly in the liver, resulting in high prevalence of secreted proteins in the serum.
Mice with established PDV6 tumors injected with the IL-10 minicircle, displayed very high IL-10 serum concentrations immediately after the injection (Fig.1A) , that subsequently stabilized in the 10 -100 ng/ml range. IL-10 was undetectable after control minicircle injection (data not shown). The IL-10 levels were sufficient to promote rejection of established PDV6 tumors (Fig.1B) . In contrast, IL-10 treatment was ineffective in IL-10Rb-/-mice (Suppl Fig.2A,B) , indicating that IL-10 acts on the host but not the tumor cells and in RAG-/-mice (Suppl. Fig.2C ), indicating the importance of 9 the adaptive immune system in the IL-10 response. Likewise, established CT26 tumors were rejected in IL-10 treated mice, but not in control mice (Suppl. Fig 3A grey lines) .
These data confirm the previously reported potent anti-tumor efficacy of IL-10 and demonstrate the usefulness of the IL-10 minicircle for further mechanistic studies. (Fig.1C, D, (12) ). These data show that IL-10 treatment leads to an increase in the frequency of IFNγ producing CD8+ T cells in the tumor.
IL-10 mediated tumor rejection does not require de-novo T cell infiltration
IFNγ induces the chemokines MIG (CXCL9) and IP-10 (CXCL10), two potent chemoattractants for IFNγ producing T cells (22) . The mRNA of MIG and IP10 was induced in the tumor but not in secondary lymphoid organs ( Fig.2A) . Both chemokines were also potently induced in the serum of IL-10 treated, tumor bearing animals (Fig.2B) .
Therefore, we asked if chemokine mediated T cell migration could be responsible for the anti-tumor efficacy of IL-10. Mice deficient for the MIG and IP10 receptor (CXCR3-/-) bearing large PDV6 tumors were treated with IL-10. IL-10 treatment induced rejection of tumors in CXCR3 -/-mice with an identical kinetic as in WT mice (Fig.2C ), indicating that CXCR3 is not essential or even rate limiting for IL-10 mediated tumor rejection.
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Since chemokine receptor usage typically shows some redundancy, T cell migration was blocked using a more general approach. To this end we used FTY720, an analog of sphingosine-1-phosphate that blocks the egress of lymphocytes from lymphoid organs (23) . First we verified that FTY720 inhibits the migration of newly activated CD8+ T cells from the lymph node to the tumor. CFSE-labeled OT-I CD8+ T cells, expressing a TCR specific for the Ovalbumin-derived peptide SIINFEKL bound to H-2Kb, were adoptively transferred into mice with established PDV6-OVA tumors. One day later We next determined the effect of FTY720 treatment on IL-10 mediated tumor rejection.
Mice with established PDV6 tumors were injected three times a week with FTY720 starting three days before minicircle injection. The efficacy of FTY720 was confirmed by analysis of the T cell numbers in the blood (Fig.3C ). The frequency of CD8+ T cells in control mice that had not received FTY720 was on average 10% of total PBMC. The frequency of CD8 T cells in the blood of IL-10 treated mice was initially comparable, but was reduced after prolonged exposure to IL-10. In FTY720 treated mice, the frequency of CD8+ T cells in the blood of was reduced to around 1% irrespective of IL-10 treatment
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showing that FTY720 inhibits T cell egress from lymphoid organs even under IL-10 treatment.
However, the blockade of T cell migration by FTY720 did not alter the anti-tumor efficacy (Fig.3D ). IL-10 induced rejection of established PDV6 tumors followed a similar kinetic in both buffer and FTY720 treated mice. Identical results were obtained in CT-26 tumor bearing Balb/C mice (Suppl Fig 3A) . Despite inhibition of de-novo T cell infiltration, IL-10 treatment increased the activity of tumor resident CD8+ T cells (Suppl.
Fig 3 C,D).
These results show that IL-10 does not require the involvement of LN CD8+ T cells but rather directly activates tumor resident CD8+ T cells.
Activated CD8+ T cells express elevated levels of IL-10Ra
To determine the mechanism underlying this differential behavior of LN and tumor derived CD8+ T cells we analyzed the IL-10 receptor expression on these cells (Fig.4A ).
Indeed, tumor-infiltrating CD8+ T cells expressed significantly higher levels of the IL-10 receptor than CD8+ T cells from the TdLN. CD4+ TILs also showed a higher expression of the IL-10 receptor compared to their LN counterparts; however the levels were lower than on CD8+ TILs, especially for effector CD4+Foxp3-TILs. NK cells and CD11b+ cells from the tumor expressed similar or slightly reduced IL-10 receptor levels when compared to the corresponding lymph node population. The IL-10 receptor expression was maintained on OT-I cells isolated from the tumor.
Host CD8+ T cells from the tumor also showed strong IL-10Ra expression in agreement with previous data ( Fig.4C and 4A ). Together, these data show that antigen mediated activation of CD8+ T cells leads to increased expression of the IL-10 receptor.
IL-10R expression on CD8+ T cells is necessary and sufficient for CD8+ T cell activation by IL-10
The high level of IL-10 receptor expression on tumor-infiltrating CD8+ T cells, regulatory CD4+ T cells and myeloid cells ( As shown above for CD8+ T cells infiltrating CT26 tumors (Fig.1C) , the frequency of IFNγ producing host CD8+ T cells infiltrating PDV6-OVA tumors was increased on average three-fold after IL-10 treatment (Fig.5C ). In the tumors of control treated mice a similar percentage of WT and IL-10 receptor deficient OT-I T cells expressed IFNγ ( In this scenario only the WT OT-I cells expressed the IL-10 receptor. In contrast to WT hosts, the frequency of IFNγ producing host CD8+ T cells infiltrating PDV6-OVA tumors was not increased in IL-10Rb-/-hosts after IL-10 treatment (Fig.5E) . However, the frequency of IFNγ producing tumor resident WT OT-I cells increased again by approximately three-fold after IL-10 treatment (Fig.5F ). (Fig.6A,B) . In tumors from control mice, around 4% of both WT and IL-10Rb-/-CD8+ T cells expressed IFNγ (Fig.6C) . In only after prolonged elevation of IL-10 and the differences were less pronounced than for CD8+ T cells (Fig.6H, I ).
IL-10R induces accumulation of antigen specific tumor resident CD8+ T cells
To confirm the preferred accumulation of WT CD8+ T cells in IL-10 treated tumors we analysed the behavior of WT and IL10Rb-/-OT-I CD8+ T cells after co-transfer into mice carrying large ovalbumin expressing tumors. In control treated mice, both T cell genotypes were present at an equal proportion in the TdLN and the tumor (Fig.7 A-C) . In IL-10 treated animals, tumor resident IL-10R proficient cells had again an advantage over IL-10R-/-OT-I CD8+ T cells, while the difference was not statistically significant in the lymph node (Fig.7 A-C) . 
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A similar effect was also observed in IL-10Rb-/-hosts indicating the requirement of the IL-10 signaling in only the CD8+ T cells (Fig 7D) . (Fig.7E,F) .
This result suggests that tumor resident CD8+ T cells proliferate in vivo in response to IL-10 treatment and that this effect is primarily induced directly in CD8+ T cells.
IL-10 activates a unique combination of STATs in tumor resident CD8+ T cells
To explain why CD8+ T cells from lymph nodes react different to IL-10 than tumor resident CD8 T cells we asked if the higher expression of the IL-10R on tumor resident CD8+ T cells would result in a differential signaling downstream of the receptor. To this end, we performed flow cytometry for phosphorylated STATs (pSTAT) in T cells. Both in CD8+ T cells isolated from the TdLN and the tumor IL-10 induced pSTAT3 (Fig.7G) . 
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However, the levels of pSTAT3 were almost 10 fold higher in tumor derived CD8+ T cells than in TdLN derived CD8+ T cells. Tumor resident CD8+ T cells also had higher levels of pSTAT3 than CD4+ TILs in response to IL-10 while LN CD8+ and CD4+ T cells displayed similar amounts of pSTAT3. Interestingly, IL-10 signaling also led to the activation of STAT1 but only in tumor derived CD8+ T cells (Fig.7G) It is important to note that tertiary lymphoid structures as described in human colon and lung cancers were not found in any of the tumors analyzed in this study and a previous study (12) , CD8+ T cells were rather equally distributed throughout the tumor tissue.
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The potent anti-tumor efficacy of IL-10 is in stark contrast to its better known immune suppressive capacity in infection and autoimmune models as well as its described contribution to the immune suppressive environment of the tumor. Experimental approach as shown in Figure 5A . 
